6 results about "Variable domain" patented technology

This disclosure relates to an immunoglobulin molecule having multiple variable domains that are each specific for a receptor, as well as heterodimeric molecules that include the multivariable domain immunoglobulin and a second heavy chain constant domain (HCCD2) of an antibody comprising a CH1 and a second Fc region (FC2), where FC1 and FC2 heterodimerize.

The present invention relates to bispecific antibodies comprising a first variable domain that can bind to an extracellular portion of the epidermal growth factor receptor (EGFR) and a second variable domain that can bind to an extracellular portion of the MET proto-oncogene, tyrosine kinase receptor (cMET). The antibody may comprise a common light chain. It may be a human antibody. The antibody may be a full-length antibody. In some embodiments, the bispecific antibody is an IgG1-format antibody having a 1:1 anti-cMET, anti-EGFR stoichiometry. In some embodiments, the antibody has a variable domain that can bind to EGFR and a variable domain that can bind to cMET.

This disclosure provides a dual variable domain immunoglobulin (DVD-Ig) molecule that binds to human STEAP1 and human PSMA, drug conjugates thereof, and methods of using them.

This disclosure provides polypeptides comprising antibody heavy chain variable domain (VH) variants, the VH variants comprising multiple antigen-binding regions and a framework comprising framework region 1, framework region 2, and framework region 3 (FWR3), wherein the VH variants have an amino acid sequence satisfying at least eight of the following criteria i)-x): i) the residue at Kabat position 19 is R, S, K, or T; ii) the residue at Kabat position 23 is T, V, A, or S; iii) the residue at Kabat position 24 is I, V, or S; iv) the residue at Kabat position 40 is selected from R, I, T, or K; v) the residue at Kabat position 43 is R, K, Q, E, or G; vi) the residue at Kabat position 44 is E, Q, A, D, or G; vii) the residue at Kabat position 45 is R, I, or L; viiii) the residue at Kabat position 76 is N or Q; ix) the residue at Kabat position 79 is Y, W, or F; and x) the residue at Kabat position 89 is V or I. The VH variant has improved basic stability and can be used as a backbone for affinity binding agents for in vitro applications, such as detecting, analyzing or separating analytes based on affinity interactions.

The present invention provides an antibody-drug conjugate (ADC), wherein the antibody is conjugated to the drug via cysteine-based site-specific conjugation, wherein the antibody comprises a first polypeptide comprising an immunoglobulin crystallizable fragment (Fc) region, at least one variable domain at the N-terminus of the Fc region, and an engineered IgG hinge region between the Fc region and the at least one variable domain, wherein the engineered IgG hinge region is heterologous to and / or mutated with respect to the Fc region to provide a predetermined number of cysteine ​​residues.

The invention as disclosed herein relates to bispecific antibodies that comprises a first variable domain that can bind an extracellular part of epidermal growth factor receptor (EGFR) and a second variable domain that can bind an extracellular part of MET Proto-Oncogene, Receptor Tyrosine Kinase (cMET). The antibody may comprise a common light chain. It may be a human antibody. The antibody may be a full-length antibody. In some aspects, the bispecific antibody is an IgG1 format antibody having an anti-EGFR, anti-cMET stoichiometry of 1:1. In some aspects, the antibody has one variable domain that can bind EGFR and one variable domain that can bind cMET.